aod9604 promotes lipolysis AOD-9604 | Peptide | High Purity AOD-9604: A Research Overview |

A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007

Published human trials mainly studied oral and intravenous forms, so subcutaneous amounts come from community practice rather than an approved clinical protocol

Watch for any adverse reactions during this period

Some users experience a plateau around weeks 10-12

There is no crash, no jitters, and no sleep disruption from the compound itself

The evidence reality This is the section that the marketing around AOD-9604 tends to skip